Publication | Open Access
Increased survival due to lower toxicity for high‐risk T‐cell acute lymphoblastic leukemia patients in two consecutive pediatric‐inspired PETHEMA trials
15
Citations
25
References
2018
Year
Patients with T-cell ALL included in the HR-11 trial showed better OS than patients in the HR-03, mostly driven by a reduction of NRM.
| Year | Citations | |
|---|---|---|
Page 1
Page 1